RiceBran Technologies Reports Fourth Quarter and Full Year 2021 Results
RiceBran Technologies (NASDAQ:RIBT) reported its 2021 financial results, showcasing an 18% revenue growth in Q4 to $8.0 million and a 19% growth for the year at $31.1 million. However, the company faced a net loss of $5.4 million in Q4, exacerbated by a $3.9 million goodwill impairment charge. Despite this, adjusted EBITDA losses narrowed by 53% in Q4 and by 66% for the year. The company aims for positive adjusted EBITDA in 2022, driven by strategic operational improvements, enhanced demand for SRB products, and a commitment to expanding its market presence.
- Revenue grew 19% year-over-year to $31.1 million in 2021.
- Adjusted EBITDA loss decreased by 66% for the year, showing improved execution.
- Demand for value-add SRB derivative ingredients grew over 30% in 2021.
- SG&A expenses dropped to 23% of sales in 2021, down from 30% in 2020.
- Net loss in Q4 2021 increased by 174% to $5.4 million due to a goodwill impairment.
- Gross profit turned into a loss of $107,000 in Q4, signaling ongoing cost pressures.
TOMBALL, TX / ACCESSWIRE / March 17, 2022 / RiceBran Technologies (NASDAQ:RIBT) (the "Company"), a global leader in the development and manufacture of nutritional and functional ingredients derived from rice and other small and ancient grains for human food, nutraceutical, pet care and equine feed applications, today announced financial results for the fourth quarter and year ended December 31, 2021.
Summary Results ( | 4Q2021 | 4Q2020 | % Chg. | Qual | FY2021 | FY2020 | % Chg. | Qual | ||||||||||||||
Revenue | $ | 8,043 | $ | 6,806 | +18 | % | Improved | $ | 31,131 | $ | 26,199 | +19 | % | Improved | ||||||||
Gross Profit (Loss) | $ | (107 | ) | $ | (47 | ) | +128 | % | Declined | $ | 442 | $ | (2,471 | ) | NM | Improved | ||||||
Operating Loss | $ | (5,634 | ) | $ | (1,825 | ) | +209 | % | Increased | $ | (10,566 | ) | $ | (11,289 | ) | (6 | %) | Improved | ||||
Net Loss | $ | (5,404 | ) | $ | (1,974 | ) | +174 | % | Increased | $ | (8,949 | ) | $ | (11,730 | ) | (24 | %) | Improved | ||||
Adj. EBITDA Loss (non-GAAP)* | $ | (437 | ) | $ | (932 | ) | (53 | %) | Improved | $ | (2,559 | ) | $ | (7,610 | ) | (66 | %) | Improved | ||||
Fourth Quarter Highlights
- Revenue grew
18% year-over-year to$8.0 million . - Net loss increased by
174% to$5.4 million including a$3.9 million charge for goodwill impairment. - Adjusted EBITDA loss (non-GAAP*) narrowed by
53% to$437,000. - Company delivered sequential improvements in monthly performance, supported by price increases and operational strategies to overcome supply chain challenges.
2021 Full Year Highlights
- Revenue grew
19% year-over-year to$31.1 million . - Company transitioned to positive gross profits, for a
24% reduction in net loss to$9 million in 2021. - Adjusted EBITDA loss (non-GAAP*) narrowed by
66% to$2.6 million . - Supply chain pressure on agricultural feedstocks drove increased interest and demand for SRB and SRB-based ingredients across a wide variety of applications.
Operational Milestones
"We overcame a challenging environment in 2021 to successfully expand our addressable market and deliver significant improvement in every financial metric," said Executive Chairman Peter Bradley. "We enhanced our value-add presence in the nutraceutical and wellness markets and made significant inroads for our core-SRB products in the companion animal market. These accomplishments will support accelerated growth, improved capacity utilization, and margin expansion in 2022, and with sustainable operating improvements in our milling operations, gives us optimism that we will transition to positive adjusted EBITDA (non-GAAP*) in 2022."
- Transition to Higher Added Value Ingredients Accelerating - Our value-add SRB derivative ingredients continue to enjoy strong demand, and our strategy to emphasize this business was validated by over
30% growth in sales from these products in 2021. We introduced new SRB products targeting the health and wellness markets and enhanced our reach in this growth category with the AIDP relationship. These actions should support growth in 2022, with upside offered by new product introductions in these and other markets. - Disruptions Provide Opportunity to Expand Addressable Market - Market and supply chain disruptions provided opportunities to accelerate the adoption of SRB in a wider range of applications. In particular, the company enhanced its position in the companion animal market by displacing other ingredients as the base for new flavor systems. Prolonged market disruption from overseas conflict would place further emphasis on alternative and domestically sourced feedstocks across a broad range of applications.
- Enhanced Capacity Utilization Offers Potential for Gross Margin Expansion - In 2021 core-SRB demand was unmet due to logistics challenges. In 2022 our largest companion animal and equine customers will be supported by a new dedicated freight partnership. New business in the companion animal category and a properly supported equine franchise should enhance core-SRB production volumes, capacity utilization and operating leverage, providing the opportunity for meaningful gross margin expansion from this business.
- Milling Operations Demonstrating Improved Performance - Following unplanned downtime in the third quarter, MGI returned to growth in the fourth quarter, and operational upgrades will support new customer wins and drive revenue growth and gross margin expansion in 2022. Operational improvements at Golden Ridge significantly reduced its drag on overall performance in 2021, and further improvement is likely in 2022, providing the opportunity to evaluate the strategic contribution of this business.
Financial Results
- Revenue trends reaccelerated in the fourth quarter. Total revenue was
$8.0 million in the fourth quarter of 2021, up from second and third quarter levels, and an18% increase from$6.8 million in the fourth quarter of 2020. Total revenue was$31.1 million in 2021, a19% increase from$26.2 million in 2020. Growth was broad-based and organic across all businesses, led by SRB derivatives and Golden Ridge, with core-SRB sales held back in the second and third quarter by logistical challenges which were mitigated in the fourth quarter offering the opportunity for better sales trends in 2022. - Company transitioned to positive gross profits for the year. Gross losses were
$107,000 in the fourth quarter of 2021, up from gross losses of$47,000 a year ago, as input inflation and a slow start to the quarter offset higher volumes and price increases later in the quarter. Gross profits were$442,000 for the full year 2021, a$2.9 million improvement from gross losses of$2.5 million in 2020. The transition to positive gross profits was driven by lower losses for Golden Ridge and over30% growth in SRB derivatives, leaving the opportunity for further margin expansion from higher core-SRB capacity utilization. - SG&A dropped to
23% of sales in 2021 from30% of sales in 2020. SG&A in the fourth quarter rose20% to$1.6 million from$1.3 million a year ago, primarily due to positive non-recurring items in the prior period. Total SG&A for the year declined11% to$7.1 million , from$8.0 million in 2020, driven by reductions in corporate headcount and outside consultants. Absent non-recurring items, in 2021 SG&A stabilized in the range of$1.7 -$1.8 million per quarter as was expected. - Losses narrowed due to transition to positive gross profits and lower SG&A. Operating losses declined
6% in 2021 to$10.6 million , from$11.3 million in 2020, despite a$3.9 million charge against goodwill in the fourth quarter. Net losses declined24% in 2021 to just under$9 million , or$0.19 per share, from nearly$12 million , or$0.29 per share, in 2020. Net losses in 2021 included a gain of$1.8 million in the first quarter for the forgiveness of the company's SBA PPP loan, and of$389,000 in the fourth quarter for the revaluation of a warrant liability. - Adjusted EBITDA (non-GAAP*) losses drop
66% in 2021 to$2.6 million . Adjusted EBITDA losses were$437,000 in the fourth quarter of 2021, a53% decline from losses of$932,000 in the fourth quarter of 2020. Adjusted EBITDA losses for 2021 were$2.6 million , a66% decline from losses of$7.6 million in 2020. For the second year in a row, the company converted over100% of incremental revenue into incremental adjusted EBITDA, reflecting improved execution and revealing the potential for operating leverage. - Balance sheet strengthened with sufficient liquidity. RiceBran ended 2021 with
$5.8 million in total cash, up from$5.3 million at the end of 2020. Cash burn was approximately$4 million in 2021. RiceBran raised$4.7 million in capital in 2021,$171,000 in the second quarter from the exercise of warrants,$3.4 million in the third quarter from the sale of common stock, and$1.1 million in the fourth quarter from refinancing Golden Ridge's term loan, which should provide sufficient liquidity to complete its business transformation in 2022 with adequate cash reserves.
"We enter 2022 with a growing portfolio of differentiated products, a broader addressable market, and greater opportunities," added Peter Bradley. "Combined with sustainable operating improvements in our milling operations, this provides us with the foundation for a structurally profitable company. In the fourth quarter we made significant progress in addressing logistics challenges, which with price increases helped reinvigorate top-line growth and margin expansion. We expect to build on these successes in 2022 with new customers helping to drive volume and margin expansion, and ultimately a transition to positive adjusted EBITDA."
Conference Call Information
RiceBran Technologies will host a conference call today, Thursday, March 17, at 4:30 p.m. Eastern Time to discuss these results. The call information is as follows:
- Date: March 17, 2022
- Time: 4:30 p.m. Eastern Standard Time
- Toll Free Dial-in number for US/Canada: 877-545-0320
- Dial-In number for international callers: 973-528-0002
- Participant Access Code: 626586
- Webcast: https://www.ricebrantech.com/investors
Following the conclusion of the live call, a replay of the webcast will be available on the Investor Relations section of the Company's website for at least 90 days. A telephonic replay of the conference call will also be available from 7 p.m. EST on March 17, 2022 until 11:59 p.m. EST on March 31, 2022 by dialing 877-481-4010 (United States) or 919-882-2331 (international) and using the passcode 44683.
About RiceBran Technologies
RiceBran Technologies is a specialty ingredient company focused on the development, production, and marketing of products derived from traditional and ancient small grains. Notably, we are global leader in the production and marketing of stabilized rice bran (SRB), and high value-added derivative products derived from SRB, as well as a processor of rice, rice co-products, and barley and oat products. We create and produce products utilizing proprietary processes to deliver improved nutrition, ease of use, and extended shelf-life, while addressing consumer demand for all natural, non-GMO and organic products. The target markets for our products include food and animal nutrition manufacturers and retailers, as well as specialty food, functional food and nutritional supplement manufacturers and retailers, both domestically and internationally. More information can be found in the Company's filings with the SEC and by visiting our website at http://www.ricebrantech.com.
Forward-Looking Statements
This release contains forward-looking statements, including, but not limited to, statements about RiceBran's expectations regarding its future financial results, sales growth, Adjusted EBITDA (non-GAAP) improvements, and SG&A. These statements are made based upon current expectations that are subject to known and unknown risks and uncertainties, including the risks that operations are disrupted by the COVID-19 pandemic and timing of profitable operations. RiceBran Technologies does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in RiceBran Technologies' filings with the Securities and Exchange Commission, including its most recent periodic reports.
Use of Non-GAAP Financial Information
We utilize "adjusted EBITDA" "Net Cash" and "Net Debt" as supplemental measures in our ongoing analysis of short term and long-term cash requirement and liquidity needs. Management uses adjusted EBITDA as an indicator of our current financial performance. By eliminating the impact of all material non-cash charges as well as items that do not regularly occur, we believe that adjusted EBITDA provides a more accurate and informative indicator of our cash requirements. Adjusted EBITDA does not represent cash flows from operations as defined by generally accepted accounting principles ("GAAP"), is not a measure derived in accordance with GAAP and should not be considered as an alternative to net income (the most comparable GAAP financial measure to adjusted EBITDA).
The tables below contain a reconciliation of net loss (GAAP) and adjusted EBITDA (non-GAAP) for the three and twelve months ended December 31, 2021 and December 31, 2020, and for Net Cash (non-GAAP) and Net Debt (non-GAAP) for the periods ended December 31, 2021 and December 31, 2020. We do not provide a reconciliation of forward-looking net loss (GAAP) to adjusted EBITDA (non-GAAP). Due to the nature of certain reconciling items, it is not possible to predict with any reliability what future outcomes may be with regard to the expense or income that may ultimately be recognized in future periods. Any forward-looking adjusted EBITDA information that we may provide from time to time consistently excludes the same items from projected net loss that are excluded from actual net loss in the table below.
Investor Contact
Rob Fink / Matt Chesler, CFA
FNK IR
ribt@fnkir.com
646.809.4048 / 646.809.2183
RiceBran Technologies
Consolidated Income Statement (GAAP)
(in
| 3 Months Ended (Unaudited) | 12 Months Ended | |||||||||||||||||||||||
| 12/31/21 | 12/31/20 | % Chg. | 12/31/21 | 12/31/20 | % Chg. | |||||||||||||||||||
Revenue | $ | 8,043 | $ | 6,806 | 18 | % | $ | 31,131 | $ | 26,199 | 19 | % | ||||||||||||
Cost of Goods Sold | (8,150 | ) | (6,853 | ) | 19 | % | (30,689 | ) | (28,670 | ) | 7 | % | ||||||||||||
Gross Profit (Loss) | (107 | ) | (47 | ) | 128 | % | 442 | (2,471 | ) | NM | ||||||||||||||
Gross Margin | (1 | %) | (1 | %) | 1 | % | (9 | %) | ||||||||||||||||
Selling, General & Admin. | (1,611 | ) | (1,337 | ) | 20 | % | (7,087 | ) | (7,971 | ) | (11 | %) | ||||||||||||
Impairment of goodwill | (3,915 | ) | - | NM | (3,915 | ) | - | NM | ||||||||||||||||
Gain (Loss) on PP&E | (1 | ) | (441 | ) | (100 | %) | (6 | ) | (847 | ) | (99 | %) | ||||||||||||
Operating Loss | $ | (5,634 | ) | $ | (1,825 | ) | 209 | % | $ | (10,566 | ) | $ | (11,289 | ) | (6 | %) | ||||||||
Interest Expense, net | (110 | ) | (122 | ) | (10 | %) | (462 | ) | (298 | ) | 55 | % | ||||||||||||
Gain on Extinguishment of PPP loan | - | - | - | 1,792 | - | - | ||||||||||||||||||
Change in FV of Derivative Warrant Liability | 389 | - | - | 389 | - | - | ||||||||||||||||||
Other Expense, net | (29 | ) | (16 | ) | 81 | % | (81 | ) | (124 | ) | (35 | %) | ||||||||||||
Loss Before Income Taxes | (5,384 | ) | (1,963 | ) | 174 | % | (8,928 | ) | (11,711 | ) | (24 | %) | ||||||||||||
Income Taxes | (20 | ) | (11 | ) | 82 | % | (21 | ) | (19 | ) | 11 | % | ||||||||||||
Net Loss | $ | (5,404 | ) | $ | (1,974 | ) | 174 | % | $ | (8,949 | ) | $ | (11,730 | ) | (24 | %) | ||||||||
Basic & Diluted Loss per Share: | $ | (0.10 | ) | $ | (0.05 | ) | 100 | % | $ | (0.19 | ) | $ | (0.29 | ) | (34 | %) | ||||||||
Weighted Avg. Shares Outstanding (Basic & Diluted): | 51,933 | 43,688 | 19 | % | 47,739 | 41,132 | 16 | % | ||||||||||||||||
RiceBran Technologies
EBITDA and Adjusted EBITDA Reconciliation (Unaudited) (Non-GAAP)
(in
| 3 Months Ended | 12 Months Ended | |||||||||||||||||||||||
| 12/31/21 | 12/31/20 | % Chg. | 12/31/21 | 12/31/20 | % Chg. | |||||||||||||||||||
Net Loss | $ | (5,404 | ) | $ | (1,974 | ) | 174 | % | $ | (8,949 | ) | $ | (11,730 | ) | (24 | %) | ||||||||
Interest Expense, net | 110 | 122 | (10 | %) | 462 | 298 | 55 | % | ||||||||||||||||
Depreciation and Amortization | 621 | 644 | (4 | %) | 2,592 | 2,621 | (1 | %) | ||||||||||||||||
EBITDA | $ | (4,673 | ) | $ | (1,208 | ) | 287 | % | $ | (5,895 | ) | $ | (8,811 | ) | (33 | %) | ||||||||
Gain on extinguishment of PPP loan | - | - | - | (1,792 | ) | - | - | |||||||||||||||||
Impairment of goodwill | 3,915 | - | 100 | % | 3,915 | - | 100 | % | ||||||||||||||||
Other Expense, net | 29 | 16 | 81 | % | 81 | 124 | (35 | %) | ||||||||||||||||
Share-Based Compensation | 292 | 260 | 12 | % | 1,132 | 1,077 | 5 | % | ||||||||||||||||
Adjusted EBITDA | $ | (437 | ) | $ | (932 | ) | (53 | %) | $ | (2,559 | ) | $ | (7,610 | ) | (66 | %) | ||||||||
RiceBran Technologies
Consolidated Statement of Cash Flows
(in
| 3 Months Ended (Unaudited) | 12 Months Ended | |||||||||||||||||||||||
| 12/31/21 | 12/31/20 | % Chg. | 12/31/21 | 12/31/20 | % Chg. | |||||||||||||||||||
Cash Flow from Operations | ||||||||||||||||||||||||
Net Loss | $ | (5,404 | ) | $ | (1,974 | ) | 174 | % | $ | (8,949 | ) | $ | (11,730 | ) | (24 | %) | ||||||||
Adjs. to reconcile net loss to net cash used in operating activities: | ||||||||||||||||||||||||
Depreciation | 576 | 589 | (2 | %) | 2,397 | 2,393 | 0 | % | ||||||||||||||||
Amortization | 45 | 55 | (18 | %) | 195 | 228 | (14 | %) | ||||||||||||||||
Share-Based Compensation | 292 | 260 | 12 | % | 1,132 | 1,077 | 5 | % | ||||||||||||||||
Impairment of goodwill | 3,915 | - | NM | 3,915 | - | NM | ||||||||||||||||||
Loss on Disposition / Involuntary Conversion of PP&E | 1 | 441 | (100 | %) | 6 | 847 | (99 | %) | ||||||||||||||||
Gain on Extinguishment of PPP Debt | - | - | - | (1,792 | ) | - | NM | |||||||||||||||||
Change in FV of Derivative Warrant Liability | (389 | ) | - | NM | (389 | ) | - | NM | ||||||||||||||||
Accretion of Interest | 98 | 95 | 3 | % | 98 | 95 | 3 | % | ||||||||||||||||
Other | (67 | ) | (66 | ) | 2 | % | - | (84 | ) | - | ||||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||||||||||||
Accounts Receivable | (1,314 | ) | (363 | ) | 262 | % | (1,332 | ) | 997 | NM | ||||||||||||||
Inventories | (271 | ) | (213 | ) | 27 | % | (566 | ) | (980 | ) | (42 | %) | ||||||||||||
Accounts Payable | (314 | ) | (58 | ) | 441 | % | 280 | (709 | ) | NM | ||||||||||||||
Commodities Payable | 257 | 271 | (5 | %) | 876 | (4 | ) | NM | ||||||||||||||||
Other | 362 | 245 | 48 | % | (69 | ) | (76 | ) | (9 | %) | ||||||||||||||
Net Cash Flow from Operations | $ | (2,213 | ) | $ | (718 | ) | 208 | % | $ | (4,198 | ) | $ | (7,946 | ) | (47 | %) | ||||||||
Cash Flow from Investing | ||||||||||||||||||||||||
Purchases of PP&E | (253 | ) | (124 | ) | 104 | % | (1,440 | ) | (1,184 | ) | 22 | % | ||||||||||||
Proceeds from Insurance on Involuntary Conversion | 1 | - | - | 639 | 250 | 156 | % | |||||||||||||||||
Proceeds from Sale of Property | 3 | - | - | 3 | 15 | (80 | %) | |||||||||||||||||
Net Cash Flow from Investing | $ | (249 | ) | $ | (124 | ) | 101 | % | $ | (798 | ) | $ | (919 | ) | (13 | %) | ||||||||
Cash Flow from Financing | ||||||||||||||||||||||||
Proceeds from Warrants Exercised | - | - | - | 171 | 12 | 1325 | % | |||||||||||||||||
Proceeds from issuances of common stock and warrants | (8 | ) | 1,661 | NM | 3,364 | 2,318 | 45 | % | ||||||||||||||||
Net Change in Debt | 2,107 | 554 | 280 | % | 2,023 | 3,354 | (40 | %) | ||||||||||||||||
Net Cash Flow from Financing | $ | 2,099 | $ | 2,215 | (5 | %) | $ | 5,558 | $ | 5,684 | (2 | %) | ||||||||||||
Net Change in Cash | $ | (363 | ) | $ | 1,373 | NM | $ | 562 | $ | (3,181 | ) | NM | ||||||||||||
BOP Cash Balance | $ | 6,188 | $ | 3,890 | $ | 5,263 | $ | 8,444 | ||||||||||||||||
Net Change in Cash | (363 | ) | 1,373 | 562 | (3,181 | ) | ||||||||||||||||||
EOP Cash Balance | $ | 5,825 | $ | 5,263 | $ | 5,825 | $ | 5,263 | ||||||||||||||||
RiceBran Technologies
Consolidated Balance Sheets
(in
| Period Ending | ||||||||||||
| 12/31/21 | 12/31/20 | % Chg. | ||||||||||
Assets | ||||||||||||
Cash and Cash Equivalents | $ | 5,825 | $ | 5,263 | 11 | % | ||||||
Accounts Receivable, net | 4,136 | 2,819 | 47 | % | ||||||||
Inventories | 2,444 | 1,878 | 30 | % | ||||||||
Other Current Assets | 810 | 1,380 | (41 | %) | ||||||||
Total Current Assets | $ | 13,215 | $ | 11,340 | 17 | % | ||||||
PP&E, Net | 15,444 | 16,367 | (6 | %) | ||||||||
Operating Lease right-of-use assets | 2,127 | 2,452 | (13 | %) | ||||||||
Goodwill & Intangibles | 527 | 4,637 | (89 | %) | ||||||||
Total Assets | $ | 31,313 | $ | 34,796 | (10 | %) | ||||||
Liabilities and Shareholders' Equity | ||||||||||||
Accounts Payable | $ | 826 | $ | 955 | (14 | %) | ||||||
Commodities Payable | 1,702 | 825 | 106 | % | ||||||||
Accruals | 1,470 | 1,137 | 29 | % | ||||||||
Leases, Current | 468 | 426 | 10 | % | ||||||||
Debt, Current | 4,690 | 2,483 | 89 | % | ||||||||
Total Current Liabilities | $ | 9,156 | $ | 5,826 | 57 | % | ||||||
Leases, Not Current | 2,048 | 2,443 | (16 | %) | ||||||||
Debt, Not Current | 1,356 | 3,107 | (56 | %) | ||||||||
Derivative Warrant Liability | 258 | - | NM | |||||||||
Total Liabilities | $ | 12,818 | $ | 11,376 | 13 | % | ||||||
Preferred Stock | 75 | 112 | (33 | %) | ||||||||
Common Stock | 326,279 | 322,218 | 1 | % | ||||||||
Accumulated Deficit | (307,859 | ) | (298,910 | ) | 3 | % | ||||||
Total Shareholders' Equity | $ | 18,495 | $ | 23,420 | (21 | %) | ||||||
Total Liabilities and Shareholders' Equity | $ | 31,313 | $ | 34,796 | (10 | %) | ||||||
RiceBran Technologies
Net Cash and Net Debt Reconciliation (Unaudited) (Non-GAAP)
(in
| Period Ending | ||||||||||||
| 12/31/21 | 12/31/20 | % Chg. | ||||||||||
Cash and Cash Equivalents | $ | 5,825 | $ | 5,263 | 11 | % | ||||||
Less: Total Debt, Current and Non-current | 6,046 | 5,590 | 8 | % | ||||||||
Net Cash (Debt) | $ | (221 | ) | $ | (327 | ) | (32 | %) | ||||
SOURCE: RiceBran Technologies
View source version on accesswire.com:
https://www.accesswire.com/693580/RiceBran-Technologies-Reports-Fourth-Quarter-and-Full-Year-2021-Results
FAQ
What were RiceBran Technologies' Q4 2021 revenue results?
How did RiceBran Technologies perform in 2021 compared to 2020?
What significant charge affected RiceBran's Q4 net loss?
What steps is RiceBran Technologies taking to improve profitability in 2022?
What was the adjusted EBITDA loss for RiceBran Technologies in 2021?
